{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"35.5","value":"18.2"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.0","upperLimit":"38.9","value":"21.2"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.0","upperLimit":"38.9","value":"21.2"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"31.9","value":"15.2"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Percentage of participants with a reduction of mean GH levels to \\< 2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) at 3, 6, 9 and 12 months","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"NUMBER","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the study treatment they have been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Months 3, 6, 9 & 12","title":"Total-group Response Rate (GH & IGF-1) Over Time (Core Phase)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}